BRISBANE, Calif., May 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.
As you might know, CareDx, Inc ( NASDAQ:CDNA ) just kicked off its latest quarterly results with some very strong...
Despite a Quarterly Revenue Decline, CareDx Optimistic About 2024 Prospects